CVAC - Despite Pfizer Moderna And AstraZeneca COVID-19 Progress Vaccine Developers Still Present Interesting Investment Opportunities

• After Pfizer / BioNTech, Moderna and AstraZeneca released their interim data from COVID-19 vaccine trials, many might think the market would be saturated with vaccine developer news.
• However, laws of supply and demand dictate that all developers that have showed signs of efficacy or a successful approach ought to benefit from high levels of interest.
• After discussing the late stage candidates close to approval, in this article I look at three opportunities amongst the field of developers the media has briefly forgotten about.
• I look at Novavax, Vaxart, CureVac and also discuss BioNTech itself.
• All four companies present contrasting investment opportunities. Novavax offers perhaps the greatest risk / reward, Vaxart the most unique opportunity, and the two MRNA developers present more than a COVID-19 vaccine.

For further details see: